A Randomised Controlled Trial of the Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy) Compared with 0.25% Desoximetasone Cream (Topicorte) for the Treatment of Scalp Psoriasis

Main Article Content

Leena Chularojanamontri
http://orcid.org/0000-0001-6625-6445
Narumol Silpa-archa
http://orcid.org/0000-0002-1678-5442
Pichanee Chaweekulrat
http://orcid.org/0000-0002-8902-4492
Chayanee Likitwattananurak
http://orcid.org/0000-0001-5687-0847
Puncharas Weerasubpong
http://orcid.org/0000-0001-8419-9704
Natchaya Junsuwan
http://orcid.org/0000-0002-0421-7106
Norramon Charoenpipatsin
http://orcid.org/0000-0003-4835-3668
Chanisada Wongpraparut
http://orcid.org/0000-0002-9014-3229

Abstract

Objective: To compare the efficacy and safety of a generic desoximetasone cream (Topoxy) with the reference form, Topicorte, for the treatment of scalp psoriasis.
Methods:
A randomised, double-blind, controlled study was conducted. Altogether, 105 patients with psoriasis lesions covering more than 10% of the scalp were randomised into three groups. The first, second and third groups received a placebo, Topoxy and Topicorte, respectively. The scalp psoriasis severities were assessed at weeks 0, 2, 4 and 8, using the Investigator Global Assessment (IGA) scale and Total Sign Score (TSS). The safety profiles of the products were assessed by the patients and physicians.
Results:
Topoxy and Topicorte were significantly more effective than the placebo in achieving at least a two-grade improvement in the IGA score from baseline at weeks 2, 4 and 8, and there were no significant differences between Topoxy and Topicorte. The TSS of both creams were significantly lower than that of the placebo at weeks 2, 4 and 8. All patients tolerated well to the therapy.
Conclusion:
Topoxy and Topicorte had comparable efficacies for scalp psoriasis., The medications were superior to the placebo in all parameters, and  had a good safety profile.

Downloads

Download data is not yet available.

Article Details

How to Cite
Chularojanamontri, L. ., Silpa-archa, N. ., Chaweekulrat, P., Likitwattananurak, C. ., Weerasubpong, P. ., Junsuwan, N. ., Charoenpipatsin, N. ., & Wongpraparut , C. . (2020). A Randomised Controlled Trial of the Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy) Compared with 0.25% Desoximetasone Cream (Topicorte) for the Treatment of Scalp Psoriasis. Siriraj Medical Journal, 72(5), 371–379. https://doi.org/10.33192/Smj.2020.50
Section
Original Article

References

1. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch. Dermatol. 2007;143(2):239-42.
2. Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435-44.
3. Fitzpatrick TB, Wolff K. Fitzpatrick's Dermatology in general medicine. 9th ed. New York: McGraw-Hill Medical; 2019.
4. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-14.
5. Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16(1):31-6.
6. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7(3):185-92.
7. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol 2006;5(4):328-32.
8. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3(4):367-73.
9. Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. J Drugs Dermatol 2013;12(12):1404-10.
10. Cornell RC, Stoughton RB. Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis. Br J Dermatol. 1981;105(1):91-5.
11. Kuokkanen K. Comparison of 0.25% desoxymethasone ointment with 0.05% fluocinonide ointment in psoriasis. Curr Med Res Opin. 1976;4(10):703-5.
12. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-43.
13. Taheri A, Cantrell J, Feldman SR. Tachyphylaxis to topical glucocorticoids; what is the evidence? Dermatol. Online J. 2013;19(7):18954.
14. Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J. Dermatol. 2012;57(4):251-9.
15. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. J Dermatolog Treat. 2018;29(2):111-5.
16. Bagel J, Nelson E. An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. J Clin Aesthet Dermatol. 2018;11(5):27-9.